This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Data availability
The data presented in this report are available on request to the corresponding author.
References
Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet Lond Engl. 2020;395:1146–62.
Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384:842–58.
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-Cell Lymphoblastic Leukemia. N. Engl J Med. 2018;378:439–48.
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31–42.
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56.
Abramson, Palomba JS, Gordon LI ML, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–52.
Zhu F, Wei G, Zhang M, Zhao H, Wu W, Yang L, et al. Factors associated with costs in chimeric antigen receptor T-cell therapy for patients with relapsed/refractory B-cell malignancies. Cell Transpl. 2020;29:963689720919434.
Erdoğan E, Yalçın K, Hemşinlioğlu C, Sezgin A, Seyis U, Kançağı DD, et al. Preliminary report of the academic CAR-T (ISIKOK-19) cell clinical trial in Turkey: characterization of product and outcomes of clinical application. Turk J Haematol J Turk Soc Haematol. 2022;39:206–10.
Ortíz-Maldonado V, Rives S, Castellà M, Alonso-Saladrigues A, Benítez-Ribas D, Caballero-Baños M, et al. CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19+ relapsed/refractory malignancies. Mol Ther J Am Soc Gene Ther. 2021;29:636–44.
Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2020;26:26–33.
Chen G, Herr M, Nowak J, Ho C, Almyroudis N, Attwood K, et al. Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant. Haematologica. 2023;108:615–20.
Buechner J, Grupp SA, Hiramatsu H, Teachey DT, Rives S, Laetsch TW, et al. Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Adv. 2021;5:593–601.
Acknowledgements
The authors thank Nathália Cristine André, Sandra Navarro Bresciani, Maristela Delgado Orellana, Lucas Botelho, Amanda Mizukami Martins, Taísa Risque Fernandes, Sâmia Rigotto Caruso, Virginia Picanço-Castro, and Patricia Bonini Vianna for their assistance. We also thank all the personnel involved in CAR-T cell manufacturing.
Funding
Fundação de Amparo à Pesquisa do Estado de São Paulo—FAPESP (process number 2013/08.135-2), São Paulo, Brazil. Butantan Institute, São Paulo, Brazil.
Author information
Authors and Affiliations
Contributions
Conceptualization: Camila D. Donadel, Gil C. De Santis, Renato Luiz Guerino-Cunha, Rodrigo T. Calado, Dimas T. Covas and Diego V. Clé; Methodology: Camila D. Donadel, Gil C. De Santis and Diego V. Clé; Statistical analysis: Thiago Eleutério Gonçalves, Camila D. Donadel and Gil C. De Santis; Data collection: Camila D. Donadel, Bruno G. Pires, Flavia Gava, Giancarlo Fatobene, Joana T. B. Faria, Gabriela V. A. Silva, Luiz Guilherme Darrigo-Junior, Renato Luiz Guerino-Cunha, and Thiago Eleutério Gonçalves; Writing—original draft preparation: Camila D. Donadel, Bruno G. Pires, Gil C. De Santis, Diego V. Clé; Writing—review and editing: Camila D. Donadel, Gil C. De Santis, Giancarlo Fatobene, Flavia Gava, Vanderson Rocha, Rodrigo T. Calado, Diego V. Clé. All authors have read and agreed to the published version of the paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Donadel, C.D., De Santis, G.C., Gonçalves, T.E. et al. Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil. Bone Marrow Transplant (2024). https://doi.org/10.1038/s41409-024-02283-6
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41409-024-02283-6